OncoTargets and Therapy

eISSN: 1178-6930pISSN: 1178-6930
JournalOpen Access

Journal formatting to fit the target journal guidelines

Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!

Aims and Scope

OncoTargets and Therapy is a peer-reviewed medical journal covering research on all aspects of oncology. The journal was established in 2008 and is published by Dove Medical Press.

Key Metrics

CiteScore
7
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.81
4
Time to Publish
time-to-publish View Chart
4  Mo

Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
  • Publisher
    DOVE MEDICAL PRESS LTD
  • Language
    English
  • Frequency
    Continuous publication
  • Article Processing Charges
    USD 2410
  • Publication Time
    16
  • Editorial Review Process
    Anonymous peer review
General Details
Publication Details
Editorial Review Detail
Information for authors
View less

Ready to spotlight your research findings?

Impress peers and journals alike with a concise, visual summary of your work.

Meets Top Publisher Standards: Essential for leading journals like Elsevier.
Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.
Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
Learn more 3000+ graphical abstracts produced with 4.8/5 customer rating
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 20%
4-6 65%
7-9 15%
>9 0%

Topics Covered

Cancer
Western blot
Overall survival
Lung cancer
Assay
Progression-free survival
Central nervous system
Hepatocellular carcinoma
Irradiation
Toxicity
Reactive oxygen species
Cell cycle
Immunotherapy
Chordoma
Epidermal growth factor receptor
Crizotinib
Lung
Colorectal cancer
Chemotherapy
Osteosarcoma

Recently Published Papers

Year-wise Publication

FAQs

Since when has OncoTargets and Therapy been publishing? Faqs

The OncoTargets and Therapy has been publishing since 2008 till date.

How frequently is the OncoTargets and Therapy published? Faqs

OncoTargets and Therapy is published Continuous publication.

Who is the publisher of OncoTargets and Therapy? Faqs

The publisher of OncoTargets and Therapy is DOVE MEDICAL PRESS LTD.

Where can I find a journal's aims and scope of OncoTargets and Therapy? Faqs

For the OncoTargets and Therapy's Aims and Scope, please refer to the section above on the page.

How can I view the journal metrics of OncoTargets and Therapy on editage? Faqs

For the OncoTargets and Therapy metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of OncoTargets and Therapy? Faqs

The eISSN number is 1178-6930 and pISSN number is 1178-6930 for OncoTargets and Therapy.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Cancer, Western blot, Overall survival, Lung cancer, Assay, Progression-free survival, Central nervous system, Hepatocellular carcinoma, Irradiation, Toxicity, Reactive oxygen species, Cell cycle, Immunotherapy, Chordoma, Epidermal growth factor receptor, Crizotinib, Lung, Colorectal cancer, Chemotherapy, Osteosarcoma.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.